The'purpose of the Histopathology Facility (HF) is to facilitate research conducted by funded investigators at Fox Chase Cancer Center (FCCC) by providing histology and pathology services including processing of cells and tissues as well as helping in the interpretation of results. The Facility's Technicians and Pathologist play a major support role in numerous research projects at the Center and their contributions have been, and continue to be of great significance in the establishment and characterization of animal models of human cancer. The Facility prepares, processes, and assists in evaluating tissues derived from experimental protocols developed by peer-reviewed, funded investigators. Most of the projects involve animal models of human cancer that require complex histological and/or cytological processing to determine morphological alterations, as well as to localize cancer-relevant gene products. The most frequently utilized services of the Facility during 2005-2009 include: laboratory animal autopsy, fixation, embedding and sectioning of paraffin-embedded tissue blocks (8,000-12,000 per year), unstained paraffin sections for immunohistochemistry (IHC) and laser capture microdissection (LCM) (9,000-14,000 per year), cryomicrotomy (200-1,500 per year), special stains (200-500 per year), immunohistochemistry (IHC) (2,100-3,700 per year), digital microphotography (3,000-5,000 per year), and interpretative histopathology (7,000- 10,000 H&E and IHC slides signed-out per year). During the last CCSG funding cycle we have seen a steady need for all services rendered and significant increase (100%) in the number of frozen sections performed. Furthermore, during 2005-2010 we consolidated new technology such as the web-based Experimental Histopathology database and introduced computerized image analysis. The HF also provides support to the Laboratory Animal Facility (LAF) in quality control and animal health monitoring activities, as well as processing support to the Biosample Repository Facility (BRF) and the LCM component of the Genomics Facility (GF). The HF was used by 39 peer-reviewed, funded investigators in all five Research Programs at FCCC, in calendar year 2009.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-49
Application #
8379815
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
49
Fiscal Year
2012
Total Cost
$57,098
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Peng, Hongzhuang; Prokop, Jeremy; Karar, Jayashree et al. (2018) Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Res 78:1200-1213
Araiza-Olivera, Daniela; Chernoff, Jonathan (2018) Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases 9:327-331
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Auerbach, M V; Heckman, C J; Darlow, S (2018) To protect or not to protect: examining reasons for sun protection among young women at risk for skin cancer. J Behav Med 41:528-536
Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7:
Ross, Kayleigh C; Chin, Kevin F; Kim, Daehwan et al. (2018) Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget 9:13324-13336
Diefenbach, Michael A; Benedict, Catherine; Miller, Suzanne M et al. (2018) Examining the impact of a multimedia intervention on treatment decision-making among newly diagnosed prostate cancer patients: results from a nationwide RCT. Transl Behav Med 8:876-886

Showing the most recent 10 out of 1280 publications